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ABSTRACT  
The present study is an attempt to synthesize nanosized guar gum carriers encapsulating celecoxib as the chemopreventive agent for 
experimental colorectal cancer (CRC).  Guar gum nanoparticles without celecoxib (eGGNPs) and celecoxib loaded guar gum nanoparticles 
(cGGNPs) were prepared by oil-in-water emulsification and in situ polymer crosslinking method. Electron microscopy, zeta potential and 
fourier transform infrared spectra analysis was used to affirm the size, stability and morphology of the nanoparticles. In-vitro drug release was 
investigated using dialysis method. Further, the effect of nanoparticles (eGGNPs & cGGNPs) was evaluated on Caco 2 colon cancer cell lines. 
Spherical guar gum nanoparticles were obtained in the size range of 200±6nm with zeta potential of -32.1mV indicating good stability of the 
GGNPs with drug loading of 30±3.2%, and drug release following zero order kinetics. The eGGNPs had no effect on Caco2 cell viability whereas 
the cGGNPs showed time and concentration dependent growth inhibition of Caco 2 cells. These findings suggest the successful preparation of 
chemopreventive nanoparticles that can be targeted as the prophylactic agent for experimental colorectal cancer. 
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Colorectal cancer is the third most common cancer 
worldwide and is one of the leading causes of mortality1. 
Genetic and environmental factors such as poor diet, lack of 
exercise, obesity, smoking and alcohol intake are thought to 
increase the risk of developing colorectal cancer2. More than 
60% of cancer deaths occur in underdeveloped and 
developing countries, many of which lack the medical 
resources and health systems to support the disease 
burden3. In India too an increase in CRC incidence rates has 
been observed in the past decade due to change in lifestyle 
and diet4,5. Additionally, economic transition from a low to 
middle income economy has increased the burden of CRC in 
India emphasizing the need to prevent or reduce the 
occurrence of CRC, a life style disease, particularly in high 
risk individuals6. 
A body of evidence indicates the role of inflammation in the 
development of cancer progression, designating it as the 
seventh hall mark of cancer7. Among the different mediators 
of inflammation, the cyclo-oxygenases belonging to the 
family of myleoperoxidases, also known as prostaglandin H 
synthases appear to be implicated in cancer. Prostaglandin-
endoperoxidse synthase 2 (COX-2) modulates cell 
proliferation, cell death and tumor invasion8. Targeting 
these enzymes has been attempted to reduce inflammation 
and progression of polyps. Specifically, clinical observations 
and case series studies have demonstrated that celecoxib, 
the COX-2 selective inhibitor, reduced the adenomatous 
polyp burden among patients with familial adenomatous 
polyposis9,10,11,12. Celecoxib possesses anti-inflammatory and 
anti-tumorigenic efficacy and has been clinically approved 
by FDA for familial adenomatous polyposis (FAP) 
patients13,14. Though effective, however, these drugs are not 
recommended for long term therapy or in high doses due to 
associated adverse effects such as cardiovascular toxicity, 
myocardial infarction, gastrointestinal toxicity, renal toxicity 
and mucosal damage15,16. To overcome the off target drug 
toxicity, nanoparticles (NPs) have piqued the interest of the 
medical community for use in cancer diagnosis, prevention, 
treatment and as delivery vectors for biologic or 
pharmacologic agents. Due to small particle size, they are 
attracted to their target tissues and have the advantages of 
targeted drug delivery to the desired site of action, 
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prolonged blood circulation of the encapsulated drug, and 
reduced drug side effects thus nanoparticle encapsulated 
drugs are preferred17,18. 
Biodegradable materials for nanoparticles such as 
polysaccharides are gaining considerable attention due to 
biocompatibility due to enhanced bio-adhesion with 
biological tissues, like epithelia and mucous membranes, 
non toxicity, abundant resources in nature and low cost in 
their processing19. Guar galactomannan commonly known as 
guar gum, a water soluble polysaccharide extracted from the 
seeds of Cyamopsis tetragonoloba, has been extensively used 
for delivery to colon due to its drug release retarding 
property and susceptibility to microbial degradation in large 
intestine20,21. Additionally, guar gum also has prebiotic 
properties i.e. it acts as a non-digestible food ingredient that 
beneficially affects the host by selectively stimulating the 
growth and/or activity of one or a limited number of 
bacteria in the colon, and thus improves host health22. Guar 
gum has been extensively studied for preparation of tablet 
coatings to achieve colon specific delivery23. More 
specifically, several nanoparticle formulations have been 
reported for the delivery of anticancer drugs such as 5-
Flourouracil, methotrexate etc. using guar gum against 
breast cancer, esophageal cancer among others24,25,26. 
Though, guar gum based nanosized materials have been 
used as drug delivery agent but literature pertaining to its 
use as prophylactic drug carriers for CRC is not available. 
Therefore, the present study aimed at preparing guar gum 
nanoparticles encapsulating celecoxib to be used as a 
targeted drug delivery system to the colon cancer as an 
effective prophylactic agent. 
2. MATERIALS AND METHODS 
2.1. Materials 
HPLC grade Di-chloromethane (DCM) and Glutaraldehyde 
(25%) were purchased from Merck Chemicals, Mumbai 
India. Guar gum powder, Span80, HPLC grade water and 
Glycerol were purchased from HiMedia Laboratories, 
Mumbai, India. Celecoxib was a gift from Ind Swift 
Laboratories Limited, Punjab, India.  
2.2 Preparation of guar gum nanoparticles (GGNPs) 
Celecoxib loaded guar gum nanoparticles (cGGNPs) as well 
as empty guar gum nanoparticles (eGGNPs) were prepared 
by oil in water emulsification and in situ polymer 
crosslinking method with slight modifications27. Briefly, 
10mg celecoxib was dissolved in 10 mL DCM (DCM without 
celecoxib for eGGNPs) and 1mL Span 80 (2%v/v) was added 
to make oil phase. 30mL of 0.5% aqueous guar gum solution 
was kept under constant magnetic stirring to which the oil 
phase was then added drop-wise. After mutual saturation of 
the oil and the continuous phase, the mixture was sonicated 
for 10 minutes (30s On/10s Off, 40% amplitude) followed by 
drop-wise addition of 10mL glycerol. Thereafter, 1mL 
gluteraldehyde (25%) was then added as crosslinker. 
Nanosuspension thus obtained was kept overnight at 37°C 
for nanoparticle formation. Nanoparticles were obtained 
after cold centrifugation at 20,000 rpm for 30 min, washed 
with 15 mL HPLC grade water and re-centrifuged. The 
yielded nanoparticles were lyophilized, harvested in micro 
centrifuge tubes and preserved in vacuum desiccator. 
2.3. Characterization 
2.3.1 Particle size and zeta potential analysis  
The particle size of the formulations was determined using 
Malvern Zeta Nano S 90 (Malvern Instruments, Malvern, UK) 
that works on the principle of dynamic light scattering (DLS) 
analyzing the Brownian motion of the colloidal particles. It 
measures the hydrodynamic diameter and poly dispersity 
index (PDI)28,29. DLS measurements were conducted with 
1mg/ml of particle emulsions in Millipore water. 
Measurements were performed in triplicate at 90° angle and 
samples were maintained at 25°C. Zeta potential was 
estimated on the basis of electrophoretic mobility under an 
electrical field using Malvern zeta potential (Nano Sight 
NS500) at 25 °C. 
2.3.2 Scanning and Transmission electron microscopy 
The size, shape and morphology of the prepared GGNP’s 
were analysed using Transmission electron microscopy 
(TEM) and field emission scanning electron microscopy 
(FESEM).  
Briefly, the sample was dried properly and kept in vacuum 
desiccator overnight prior to sample preparation. After 
drying, the sample was fixed on carbon coated tap placed in 
an aluminium stub mounted in a sputter coater unit for gold 
sputtering run for 30s and scanning was performed in 
secondary electron mode at voltage 5kV. 
A drop of water suspension of the GGNPs was mounted on a 
carbon coated copper grid (CCG), air-dried and stained with 
uranyl acetate and lead citrate and examined at 80kV 
accelerating voltage at JEOL Transmission Electron 
Microscope, JEM-1400Plus (JEOL, Tokyo, Japan) equipped 
with XR81M-B Camera (Advanced Microscopy Techniques 
Corp, Woburn, MA, United States). Digital electron 
micrographs were acquired using AMT Image Capture 
Engine V602 software (Advanced Microscopy Techniques 
Corp, Woburn, MA, United States). 
2.3.3 Fourier transform infrared spectroscopy 
FTIR spectra of pure celecoxib, guar gum, eGGNP’s and 
cGGNPs were recorded to observe for any drug-polymer 
interaction. FTIR spectrum was recorded with thermally-
controlled diode laser in the spectral region of 4000–500 cm-
1 using thermo scientific, Nicolet iS50 FT-IR.   
2.3.4 X-ray Diffraction  
Powder X ray diffraction (XRD) studies were carried out 
using Brukner D8 Advance X-ray diffractomer equipped with 
Cu-Kα radiation source (λ = 1.541 A) and step size of 0.015° 
under the accelerating voltage of 40 kV and 25 mA.  
2.4 Drug loading and In-vitro drug release 
A stock solution of celecoxib was prepared for standard 
curve as described earlier30. The λ max of celecoxib was 
determined by scanning suitable dilution of stock. The drug 
loading of celecoxib in nanoparticles was determined by 
dissolving drug loaded-NP’s (5mg) in 1:1 ratio of 
DMSO:deionised water (5ml). Samples were rotated for 24h 
at 50 rpm to ensure complete dissolution. eGGNPs were 
treated identically. The concentration of celecoxib in 
resulting solution was determined by measuring absorbance 
at 252nm with spectrophotometer using eGGNPs as blank 
solution. All samples were analyzed in triplicate. Drug 
loading percentage was calculated as below: 
Drug loading (%) = (Weight of celecoxib loaded in NPs/ 
Weight of NPs)×100 
Dialysis technique was adopted to carry out the release 
experiments. Celecoxib release profiles were determined by 
suspending drug loaded NPs (20 mg) in PBS (2 ml) at pH 7.4 
and poured in the dialysis bag (5 kDa). 100ml bath fluid 
(PBS; pH 7.4) incubated at 37 ◦C while magnetic stirring at 
50rpm was used. The released media was removed and 
replaced with fresh buffer. The concentration of celecoxib in 
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the release media was determined using the UV detection 
method described above. The absorption of supernatant 
collected from blank NPs was subtracted from absorption of 
supernatant collected from loaded NP’s. 
2.4.1 Kinetics of drug release 
The cumulative amount of celecoxib released from GGNPs at 
different time intervals were fitted to zero order kinetics 
using Least Squares Method of analysis to find out whether 
the drug release from the formulations is providing a 
constant drug release. The data were further fitted to first 
order kinetics31, Higuchi model32 and Power law model33 to 
find out the drug release mechanism from the formulations. 
The percent of drug released from the formulations was 
plotted against time on log-log scale, and analyzed for 
linearity using Least Squares Method. The regression 
coefficients were calculated and used to find the fitness of 
the data. To analyze the drug release kinetics and 
mechanism, data were analysed using the following four 
models i.e Zero order, Dt = ko·t; First Order, Qt=Q0 e−kt; 
Higuchi Model, Qt = KH√t; Power Law Model, Dt = Dα·kptn. 
Where Dt represents amount of drug released at time t and 
k0, k1, kH, kp represents zero order release constant, first 
order release constant, Higuchi constant and Korsemeyer–
Peppas constant respectively; Q is the cumulative amount of 
drug released in time t, Dt is the amount of drug released in 
time t, Dα is the amount of drug released after time α; n is an 
exponent that characterizes the diffusional release kinetic 
mechanism in the Power law model. The data were analyzed 
for initial 50% release only. The values of regression 
coefficients (R2) were determined by fitting the release data 
into respective equations. 
2.2.7 In vitro cytotoxicity measurements 
To assess the cytotoxicity of GGNPs (loaded and blank) MTT 
assay was employed as per Mossmann et al., 200034. Caco-2 
cell line, procured from Cell repository, National Centre for 
Cell Sciences, Pune, India, was maintained in Minimum 
essential medium supplemented with penicillin 10U/mL, 
Streptomycin 100µg/mL and 20% heat inactivated FBS, by 
incubating at 37°C in a humidified atmosphere with 5% v/v 
CO2 in carbon dioxide incubator. Caco 2 cells were seeded 
(105 cells/ml) into 96-well plate and allowed to incubate for 
24h.Thereafter, the media was changed with fresh growth 
media. Both blank as well as celecoxib loaded GGNPs (20µL) 
in different concentration (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, and 
1mg/ml) were added to each well and incubated with the 
cells for 24, 48, 72 h. After respective time interval of 
treatment, 20µL of MTT reagent (5mg/mL) was added to 
each well and incubated for 4h. Thereafter, media was 
removed completely and DMSO (150µl) was added to each 
well to dissolve the formazan crystals. Absorbance was 
measured at 570nm using ELISA reader (TECAN Infinite 
M200). Results were expressed in terms of %survival of cells 
with treatment to that of untreated cells and were calculated 
as (OD of test/OD of control)×100. All tests were performed 
in triplicate and repeated thrice. 
3. RESULTS 
3.1 Guar gum nanoparticles preparation 
It was observed that mean particle diameter decreased from 
511 nm to 200 nm with varying sonication time from 0 to 10 
minutes. The increase in the sonication time also decreased 
the poly disparity index of the solution making it more 
homogenous. 10 min sonication of the formulation resulted 
in nanoparticles of 200±6.89 nm size with pDI of 0.058 
(Table 1). 
Table 1: Effect of sonication time on size of GGNP’s. Values 
are mean±SD. 
Sonication time Average size Average pDI 
0 511±10.43 1.3±0.370 
2 416±17.35 1.19±0.269 
4 353±17.35 0.45±0.127 
6 293±34.96 0.315±0.130 
8 218±34.96 0.216±0.0393 
10 200±6.89 0.058±0.0269 
 
3.2 Characterization 
3.2.1 Particle size and zeta potential analysis 
The mean particle size of empty as well as celecoxib loaded 
GGNPs was 200± 6 nm with narrow range size distribution 
and low poly dispersity index values (<0.1.) as measured by 
DLS method. The ζ potential of eGGNPs was -35.9mV 
whereas that of cGGNPs was -32.1mV (Figure 1).
 
 
Figure 1: Zeta potential of (a) eGGNPs  and (b) cGGNPs 
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3.2.2 Field emission scanning electron microscopy and 
Transmission electron microscopy 
The surface morphology and internal structure was 
monitored using FESEM and TEM and it was interesting to 
observe that the prepared nanoparticles possessed nearly 
smooth surface and spherical shape (Figure 2). Transmission 
electron microscopy image of GGNPs also showed spherical 
particles of 100–200 nm size with capsular structures and 
homogenous shells (Figure 3). Most of the particles appeared 
small, individual and distinct but the appearance of some 
large particles was due to aggregation of smaller particles. 
 
 
Figure 2: FESEM images illustrating morphology of (a) eGGNP; (b) cGGNP. 
 
Figure 3: TEM micrograph of (a) eGGNPs; (b) cGGNP’s. 
 
3.2.3 Fourier transform infrared spectroscopic analysis 
FTIR spectra of Guar gum, Celecoxib, eGGNPs and cGGNPs 
were recorded to compare the changes in their chemical 
structure and to study the drug polymer interactions. There 
was no appearance or disappearance of peaks in the 
formulation when compared with guar gum spectra, which 
confirmed the absence of chemical interaction between drug 
and polymer. The region of FTIR spectra between 3000 and 
2800 cm−1 shows C H stretching modes. It was observed 
that two distinct prominent peaks were present in blank as 
well as loaded nanoparticles but not in guar gum indicating 
successful in-situ crosslinking (Figure 4). 
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Figure 4: FTIR Spectra of (a) Guar gum; (b) Celecoxib; (c) eGGNP’s; and (d) cGGNP’s. 
 
3.2.4 Wide angle X-ray diffraction 
The X-ray diffraction (XRD) pattern of empty guar gum 
nanoparticles and Celecoxib loaded guar gum nanoparticles 
revealed that empty GGNP’s had amorphous structure while 
encapsulation of celecoxib resulted in slight increase in 
crytallinity in cGGNPs as a small peak was observed around 
20 θ (Figure 5). 
 
 
Figure 5. XRD spectra of (a) eGGNP’s and (b) cGGNPs. 
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3.3 Drug loading and drug release in vitro 
The loading capacity is the amount of drug loaded in the 
nanoparticles and it was 30% ±3.2 in cGGNP’s. Further, the 
time dependent cumulative release profile of cGGNPs was 
analyzed for a period of 22h. The release data was fitted into 
four kinetic models (Figure 6). Based on regression 
coefficient analysis R2 was highest for power law model 
followed by Zero order model but the value of slope was 
close to unity for Power law model. Thus, it was concluded 
that the release followed time dependent Zero order kinetics 
(Table 2).  
 
 
Figure 6: (a-d) Zero order, First order, Higuchi model, Power Law model of cumulative release percentage of celecoxib from 
cGGNPs. 
Table 2. Regression coefficient (R2) for cGGNP’s after fitting in the in-vitro drug release data to four different mathematical 
models of drug release kinetics. 
R2 Zero order R2  First order R2  Higuchi model R2  Power Law model 
0.9890 0.7895 0.9325 0.9985 (Slope 1.02) 
 
3.4 Cytotoxicity assay 
The effect of eGGNPs as well as cGGNP’s on growth of colon 
cancer cell line Caco-2 was evaluated. Since biocompatibility 
and safety of guar gum nanoparticles is a prerequisite for its 
clinical use, eGGNP’s were evaluated for any toxicity against 
Caco-2 cell line and it was interesting to observe that 
eGGNP’s had no effect on viability of Caco-2 cells. Whereas, 
cGGNP’s inhibited the growth of Caco-2 cells in a time and 
concentration dependent manner but the growth inhibition 
was less compared with pure celecoxib (Figure 7).  
 
Figure 7: Effect of cGGNP’s on viability of Caco-2 cell line. 
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4. DISCUSSION 
Colorectal cancer, a lifestyle disease, is a leading health 
problem globally. Chemopreventive agents such as non-
steroidal anti-inflammatory drugs (Celecoxib, Sulindac, 
Aspirin) are an attractive alternate which can be developed 
into potent prophylactic agents. Major limitations in NSAID 
use for chemoprevention are the side effects associated with 
high doses and long term use. Biodegradable nanoparticles 
have the ability to overcome such limitations as they offer 
targeted delivery of drug, enhanced penetration and 
biocompatibility. Therefore, an attempt was made to 
encapsulate celecoxib in guar gum nanoparticles for colon 
specific delivery. In the present study, celecoxib loaded guar 
gum nanoparticles were successfully prepared by oil in 
water emulsion in-situ polymer crosslinking technique. The 
composition of emulsion was kept constant as reported by 
Sarmah et al., 200927 but the sonication time was varied to 
check the effect of sonication time on particle size. The 
increase in the sonication time not only decreased the size of 
the particles but also decreased the poly disparity index of 
the solution making it more homogenous and hence more 
suitable for drug delivery. The nanoparticles were 
characterized by DLS, TEM and FESEM, which confirmed 
nanosized particles with smooth spherical shape and 
homogeneous distribution which corroborates with earlier 
studies25. These scientists have also prepared guar gum 
nanoparticles in similar size range and similar morphology. 
Further, a high ζ potential, either positive or negative, is 
generally required to ensure stability. In general, systems 
with ζ potential >±30 mV are considered pharmaceutically 
stable because of particle–particle repulsion (i.e., aggregation 
is avoided), whereas particles between − 10 and + 10 mV are 
considered approximately neutral35. The ζ potential of both 
eGGNPs and cGGNPs was higher than -30mV indicating 
moderate stability of the formulation. Additionally, the drug 
polymer interactions were analyzed by FTIR spectroscopy 
and the absence of drug-polymer interactions were 
confirmed as there was no appearance or disappearance of 
peaks in eGGNPs compared with cGGNPs. Further, the XRD 
spectra revealed that the encapsulation of celecoxib resulted 
in slight increase in crystallinity of the nanoparticles. The 
results are in agreement with earlier reports by Mudgill et 
al., 201236 where they have analyzed the FTIR spectra and 
XRD pattern of guar gum.  
Sarmah et al., 201125 have reported that best loading of 
tamoxifen citrate was achieved by using DCM as drug loading 
solvent. Celecoxib also showed good solubility in DCM 
therefore, DCM was used as drug loading solvent that 
resulted in moderate drug loading in GGNP’s. Further, the 
release profile of celecoxib from nanoparticles indicated 
delayed release, a suitable characteristic for colon specific 
delivery using oral route of administration. It can also be 
concluded from the release kinetics that the drug release is 
independent of amount of drug entrapped in the 
nanoparticles but is due to opening of polymeric chain due to 
swelling. Additionally, erosion of polymeric chain can also be 
a factor in the release of the drug. Similar results have been 
reported by Sarmah et al, 201125 where guar gum 
nanoparticles prepared by similar technique followed zero 
order kinetics of drug release. 
The safety analysis of GGNP’s on Caco 2 cells showed that the 
eGGNP’s did not affect the viability of Caco-2 cells indicating 
that the nanoparticles were non-toxic and safe to use. 
Furthermore, the celecoxib loaded nanoparticles were less 
effective than free drug in reducing the viability of Caco-2 
cells that may be attributed to the fact that nanoparticles 
release drug slowly and colonic microbiota degrades the 
polysaccharide chain thereby releasing the drug but in 
absence of these factors drug remains inside nanoparticles 
and had limited effect on the viability of cells. These results 
suggest that due to encapsulation of drug in guar gum matrix 
its availability is decreased, release of drug from cGGNP’s is 
delayed leading to lower inhibitory potential of cGGNP’s 
compared with pure celecoxib. Moreover, in vitro cell culture 
model is likely to be incapable of exhibiting inhibition of cell 
viability under these conditions, since drug exposure and 
uptake is not a limiting factor in this model. 
5. CONCLUSION 
Spherical nanoparticles of guar gum encapsulating celecoxib 
were successfully prepared by oil-in-water emulsification 
and in situ polymer crosslinking method. Delayed release of 
drug from nanoparticles following Zero order kinetics was 
observed. It clearly demonstrated that the nanoparticles are 
capable of retarding the rate of release of celecoxib and 
increase in the residual time until it reaches the colon, where 
microbial degradation of guar gum may help in the release of 
drug from nanoparticles. Further, the safety of guar gum 
nanoparticles was established thereby making it an ideal 
candidate for targeted delivery of chemopreventive drug 
celecoxib against colon cancer in highly susceptible 
individuals.  
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